Harvard Business Review

FEBRUARY 17, 2011

Venture capitalists are increasingly interested in emerging markets, and in working with local funds based in those markets (despite the fact that reverse innovation in venture capital seems counterintuitive). In contrast, emerging-market VCs such as Nadathur Holdings (established in 2000 by N.S.

Marketing 15

Marketing Venture Capitalist Biotechnology IPO 15

Skip Prichard

JULY 22, 2019

Bezos’ approach works especially well when the innovation requires overcoming a lot of market/demand uncertainty (will people buy it?) Unfortunately, many of us have developed expertise in only one field (software engineering, information technology [IT], marketing, biotechnology, automobile manufacturing, the food industry, etc.

Innovation 80

Innovation Social Capital Reputation How To 80

The Horizons Tracker

NOVEMBER 29, 2023

Numerous companies are now addressing market and regulatory demands by actively seeking to enhance the demographic diversity of their corporate boards. Moderna, a prominent pharmaceutical and biotechnology firm, adopted an unconventional approach utilizing RNA technology to develop one of the COVID-19 vaccines.

Diversity 106

Diversity Innovation Biotechnology Short-term 106

Harvard Business Review

JULY 11, 2018

However, young people are less common in other industries such as oil and gas or biotechnology, where the average age is closer to 47. Jeff Bezos and Amazon have moved far beyond selling books online, and Amazon’s future market cap growth rate was highest when Bezos was 45.

Succession 15

Succession IPO Entrepreneur Biotechnology 15

Harvard Business Review

MAY 7, 2018

She was on the legal compliance team at a fast-growing biotechnology company. Her role was to work with marketing to ensure that promotional campaigns and materials were in line with government guidelines. Karen had always been invited to key marketing meetings, but she noticed that more and more meetings were happening without her.

Restructuring 13

Restructuring How To Compliance Biotechnology 13

Harvard Business Review

OCTOBER 26, 2011

Their behavior displays promising parallels to the early days of the biotechnology industry. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive.

Energy 11

Energy Finance IPO Biotechnology 11

Harvard Business Review

MARCH 11, 2014

Start-up companies tend to cluster in industries favored by venture capitalists (like biotechnology or information technology) or ones where there are relatively low barriers to entry (like restaurants). In these markets if existing companies don’t rise to the innovation challenge, no one will.

Innovation 8

Innovation Venture Capitalist Company Supply Chain 8

Harvard Business Review

NOVEMBER 15, 2016

In contrast, New England has increasingly become a hub for ventures in life sciences; the first three-quarters of 2016 saw almost 60% of VC investments in New England go to ventures in biotechnology and medical devices. Witness the case of Uber, which has a market valuation exceeding $60 billion and is still a privately held company.

Biotechnology 8

Biotechnology Drucker Software Entrepreneur 8

Harvard Business Review

APRIL 27, 2012

but the emerging markets boom has generally been more about catching up than exploiting cutting-edge technology.). The only exception was in the late 1990s, when excitement over how much the Internet was going to change everything spurred an investment bubble that briefly drove real growth.

Stephenson 16

Stephenson Innovation Biotechnology eBook 16

Harvard Business Review

JUNE 21, 2013

Given the forecasts of uncertain global economic growth, we might expect companies to hold off from hiring new employees and to limit whatever international hiring they do to emerging markets. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Asia into North America).

Telecommunications 9

Telecommunications Health Care Talent Management Biotechnology 9

Harvard Business Review

MARCH 28, 2012

This means they're buying drugs that could be similar to others already on or coming soon to the market. No company should confuse the strategy of buying into a big market with buying innovation that will bring tomorrow's growth. The market reaction to all of this was mixed, but the trajectory was set for one way: higher.

Innovation 13

Innovation Company Biotechnology CFO 13

Harvard Business Review

MARCH 13, 2012

And of course that's true — but the commodities market has been booming only in recent years, and the bank's track record is long and impressive. Is it possible that local funding could help bolster tourism in Florida, biotechnology in California, publishing in New York, and agriculture in Iowa?

Biotechnology 10

Biotechnology Real Estate Tourism Banking 10

Harvard Business Review

AUGUST 17, 2015

There was a spike in the 2000s when Venezuela began to provide petroleum at deeply discounted market prices, and that peaked just before the 2008-09 financial crisis. It is probably the best, most well-trained workforce at the cheapest labor-market price that any international investor could find anywhere in the world.

Biotechnology 8

Biotechnology Tourism Human Capital Pharmaceuticals 8

Harvard Business Review

FEBRUARY 22, 2013

Cephalon's IPO was in 1991, part of the second wave of biotechnology companies to sell shares to the public. Baldino moved aggressively to bring Provigil to market. Baldino sought to convince thought leaders of the therapeutic benefit, prove the drug worked, and then market it to the needy community. By 2010, sales exceeded $2B.

Productivity 8

Productivity Products Biotechnology IPO 8

Harvard Business Review

MAY 10, 2016

After all, if acquisitions pay off they can provide a transformational antidote to a slowing core market and declining margins. Gillette dominated the men’s shaving market with its Mach series of razors.

Strategy 8

Strategy Company Biotechnology Franchising 8

Harvard Business Review

MARCH 2, 2012

As global companies focus their strategies on developed and emerging markets, they require substantial cadres of leaders capable of operating effectively anywhere in the world. French pharmaceutical company Sanofi recently acquired Boston-based Genzyme to tap into America's intellectual capital in biotechnology.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

Strategy Driven

NOVEMBER 18, 2019

This increased the need for care items for the elderly and there are plenty of gaps in the market for the healthcare sector. There have also been great leaps forward in biotechnology and even people without investment experience in the industry can find a niche sector to become involved in.

Health Care 67

Health Care Biotechnology Energy Insurance 67

Harvard Business Review

JUNE 3, 2013

Is the problem that P&G produces outstanding specialists in marketing but not general managers who can run the business? pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Where was its leadership bench? What kind of signal did this choice send to P&G''s top managers?

Succession 8

Succession Telecommunications Biotechnology Real Estate 8

Harvard Business Review

OCTOBER 1, 2014

But wait a minute – is starting more new businesses always a good thing?

Entrepreneur 11

Entrepreneur Biotechnology Real Estate Innovation 11

Harvard Business Review

MARCH 8, 2013

government is often portrayed as providing a safeguard against market failure. Elsewhere, I have called this role, which entails creating and shaping markets more than "fixing" them, " the entrepreneurial state.". In a business context, the U.S. government's risky investments have had for technology-based corporations.

Venture Capitalist 8

Venture Capitalist Biotechnology Fashion Innovation 8

Harvard Business Review

SEPTEMBER 14, 2011

Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines. It is commonly believed that emerging market companies tap Western R&D talent in order to 'move up the value chain.'

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

FEBRUARY 16, 2016

If their projections turn out to be right, we should get ready for a bumpy road ahead, with market volatility and negative surprises. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Boards are clearly aligned with business leaders and executives on their outlooks for 2016.

Politics 8

Politics Telecommunications Policies Biotechnology 8

Harvard Business Review

OCTOBER 22, 2013

In order to do this, your company needs a process to source radical ideas that can catapult your business to new heights, open up new markets, or bring in completely unfamiliar profit streams. But in today’s ever-connected world, finding radical ideas seems to be getting tougher for companies. Use Convergence Thinking.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

JUNE 16, 2016

To understand the nature of the problem, let’s look at how penicillin was brought to market. Profit-driven companies, on the other hand, feel so much pressure to go to market that they often pass on ideas with vast potential. The Valley of Death.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

JULY 16, 2013

pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., The industry breakout was done using eight major sectors (similar to those in the Global Industry Classification Standard system): Consumer Discretionary (e.g., banking & financial services, insurance, real estate); Health Care (e.g.,

Telecommunications 8

Telecommunications Biotechnology Health Care Real Estate 8

Harvard Business Review

OCTOBER 23, 2014

That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They’re also sharing risk. The new business model has yet to solidify, and the leaders have yet to emerge. The positions are there for the taking. But not for long. The options are tangible.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

OCTOBER 16, 2013

Or Chipotle, $12 billion market value right now based in Denver. Under Armour, athletic-wear company based in Baltimore. Groupon in the social commerce space, based in Chicago. I think venture capitalists do play a role.

Venture Capitalist 10

Venture Capitalist Company Biotechnology Transportation 10

The Horizons Tracker

DECEMBER 30, 2019

Location has always been vital for startups, both in terms of providing ready access to human capital to help develop the startup’s proposition, but also to provide ready access to a local market to help develop momentum. This has prompted many of the fastest growing companies of our age to congregate in the same places.

Biotechnology 57

Biotechnology Human Capital Travel Entrepreneur 57

Harvard Business Review

FEBRUARY 19, 2015

Or pay a freelance consultant to do market research? They “carved out time on nights and weekends” to do research and market analysis. ” Kate left her job at PerkinElmer in February 2014; the next month, she and her business partner started ORIGƷN, a Boston-based biotechnology company. Patch weak spots.

Project 8

Project Outsourcing Learning-by-Doing Commitment 8

Harvard Business Review

FEBRUARY 3, 2015

Uzzi and another colleague, Jarrett Spiro, also discovered that this pattern held across sectors as disparate as the Broadway mu­sical industry and biotechnology. Learn more about your market value. Be a guest speaker at a local or national event. Use it to build or strengthen your brand around a particular area of expertise.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

MARCH 17, 2014

An estimated 250 funds are actively raising capital in a market that the Global Impact Investing Network estimates at $25 billion. In impact investing, we need to find a way to place that same premium on social impact by valuing the public good being created – just like we do in early stage R&D in science, IT, health, and biotechnology.

Development 9

Development Microfinance Biotechnology Exit Strategy 9

Harvard Business Review

NOVEMBER 29, 2016

It will increasingly help government health agencies, payers, and providers to make decisions about such issues as drug discovery, patient access, and marketing.

Pharmaceuticals 8

Pharmaceuticals Incubator Health Care Biotechnology 8

Harvard Business Review

MARCH 5, 2012

Thus, the decline of manufacturing is not completely a result of "natural" market forces. This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. By subsidizing other industries so generously, we have tilted the scales away from manufacturing.

Health Care 9

Health Care Biotechnology Industry Policies 9

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. Over the past five years have new competitors entered the market and captured 10% share by targeting our customers with a different value proposition than what we offer? To illustrate this, consider that patent applications in the U.S.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

JUNE 12, 2012

trillion in government support for seven "strategic emerging industries," including alternative energy, biotechnology, next-gen IT, high-end manufacturing equipment, and advanced materials. A decade from now we may look back at China's 12th Five-Year Plan as the seminal document of the early 21st century. It pledges $1.5

First-mover Advantage 9

First-mover Advantage GDP Technology Biotechnology 9

Harvard Business Review

MAY 15, 2015

Mary Shelley told us nothing about the future of biotechnology, but the popularity and plausibility of Frankenstein: The Modern Prometheus tells us a lot about 1818’s fears and aspirations for technology and its relation to society. Taken as a whole, science fiction’s predictions do not outperform random chance.

Class 8

Class Open-book Politics Biotechnology 8

Harvard Business Review

NOVEMBER 9, 2016

While it’s understandable that stock and currency markets would react this way to the outcome of the election, I believe that it’s somewhat of an overreaction. The price of steel is set in international markets and is subject to high cyclical variations. president. Four out of five avocados sold in the U.S.

Cooper 14

Cooper Long-term Industry Health Care 14